NIH 2008

Abstract

Objective

To evaluate the clinical impact and cost-effectiveness of HLA-B*5701 testing to guide selection of first-line HIV regimens in the United States.

Design

Cost-effectiveness analysis using a simulation model of HIV disease. The prevalence of HLA-B*5701 and the probabilities of confirmed and unconfirmed severe systemic hypersensitivity reaction (HSR) among patients taking abacavir testing HLA-B*5701 positive and negative were from the PREDICT-1 trial. The monthly costs of abacavir and tenofovir-based regimens were $1,135 and $1,139; similar virologic efficacy was assumed and this assumption was varied in sensitivity analysis.